知镜 Cognispect · 医学文献与研究工作台

Blood-based RNA biomarker for the early detection of ovarian cancer.

Wilhelm J, Kumar A, Vasiyani H, Mamidi N, Sun Z, Gogna A, Bhoopathi P, Gogna KC, Salyer C, Lu A, Chougoni KK, Gardner AN, Poklepovic AS, Nagane M, Shree KS, Rakha EA, Selvendiran K, Maxwell GL, Bakkum-Gamez JN, Harrington SP, Farid EA, Traficante N, Bowtell D, Collier CD, Drexler RZ, Kramer C, Mullen MM, Tzankov A, Mertz KD, Watanabe J, Nagai S, Chiyoda T, Yamagami W, Masuda K, Garre E, Landberg G, Kolin DL, O'Connor C, Ackroyd SA, Salhia B, Gehrig PA, Singh A, Bernas T, Challa A, Sriperumbuduri S, Wages NA, Lewis J, Hoang L, Kwon JS, Haslbauer JD, Kühnel MP, Soong TR, Taylor S, Zuazo C, Beck T, Demeure MJ, Radke MR, Darabi S, Connolly D, Norquist BS, Yachida N, Suda K, Yoshihara K, Chang TY, Martin P, Won KJ, Wang TL, Shih IM, Pisanic TR, Dhaliwal TK, Jayaprakash V, Adeshina B, Hong S, Blanca A, Braxton DR, Castro CM, Swisher EM, Tsung A, Lengyel E, Domchek S, Redmond WL, Luo Y, Mogensen O, Winn RA, Rueda BR, Drapkin R, Godwin AK, Buckanovich RJ, Nephew KP, Luque RJ, Lopez-Beltran A, Coleman RL, Von Hoff D, Sidransky D, Ackermann M, Jonigk D, Grossman SR, Manchanda R, Gogna R, Madan E.
Nature medicine · 2026-11-10 · PMID 43009642

文献摘要

Flower-Win/Lose signaling underlies a tumor-host fitness conflict in ovarian cancer, in which tumor-derived exosomal Tu-stroma reduces the fitness of surrounding host cells, favoring tumor expansion within host tissues. High-grade serous carcinoma (HGSC), the most prevalent histotype of epithelial ovarian cancer and leading cause of ovarian-cancer-related mortality, arises from serous tubal intraepithelial carcinoma (STIC), a noninvasive precursor typically identifiable only by histopathologic examination of excised fallopian tube tissue. Here we evaluated Tu-stroma, a tumor-associated long noncoding RNA enriched in serum extracellular vesicles (EVs), as a circulating biomarker in STIC and early-stage HGSC, representing the earliest histopathologically defined phases of disease. Tu-stroma was quantified in serum EVs from 506 individuals with histologically normal adnexa, benign-adnexal lesions, isolated STIC and HGSC across International Federation of Gynecology and Obstetrics (FIGO) stages I-IV. Normalized EV Tu-stroma ΔC T values were elevated in STIC (n = 43) and HGSC (n = 232) versus controls (n = 143) and benign-adnexal lesions (n = 88), including premenopausal women (controls = 57, benign = 34, STIC = 32, HGSC = 88). In paired receiver operating characteristic analyses, Tu-stroma showed higher discrimination than cancer antigen 125 (CA125) for STIC versus controls (area under the curve (AUC) = 0.99 versus 0.59, P < 0.001) and benign-adnexal masses (0.99 versus 0.31, P < 0.001), and for HGSC versus controls (AUC = 0.99 versus 0.96, P = 0.001) and benign-adnexal masses (0.98 versus 0.84, P < 0.001). Tu-stroma showed no systematic elevation across inflammatory or physiologic comparators (n = 116) or nonovarian malignancies (n = 160), each assessed against healthy controls (n = 100), supporting disease-context specificity. Modeled risk-enriched contexts yielded predictive values compatible with intended-use populations. These findings identify Tu-stroma as a candidate EV-RNA marker associated with pre-invasive and early HGSC biology. Prospective evaluation in consecutively enrolled real-world cohorts is required to validate diagnostic performance, predictive value and clinical utility.

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。